AssetMark’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.8K Buy
541
+162
+43% +$5.87K ﹤0.01% 2254
2026
Q2
$13.4K Buy
379
+182
+92% +$5.38K ﹤0.01% 2342
2026
Q1
$5.46K Hold
197
– – ﹤0.01% 2530
2025
Q4
$4.28K Hold
197
– – ﹤0.01% 2516
2025
Q3
$2.98K Sell
197
-50
-20% -$619 ﹤0.01% 2516
2025
Q2
$2.78K Buy
247
+77
+45% +$835 ﹤0.01% 2326
2025
Q1
$1.72K Hold
170
– – ﹤0.01% 2203
2024
Q4
$2.01K Buy
170
+32
+23% +$378 ﹤0.01% 2120
2024
Q3
$1.59K Hold
138
– – ﹤0.01% 1920
2024
Q2
$1.46K Buy
+138
New +$1.51K ﹤0.01% 1796

Other funds holding ROIV

AssetMark's ROIV Position: Q3 2026 in Review

AssetMark increased its Roivant Sciences (ROIV) stake by 43% in Q3 2026, buying an estimated $5.87K and bringing the position to 541 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

AssetMark first reported a position in ROIV in Q2 2024 and has held it in 10 quarters since. 405 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • AssetMark held 541 shares of Roivant Sciences worth $19.8K as of Q3 2026.
  • AssetMark bought 162 Roivant Sciences shares in Q3 2026, an estimated $5.87K.
  • Roivant Sciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2254 holding.
  • AssetMark first reported a position in Roivant Sciences in Q2 2024 and has held it in 10 quarters since.
  • 405 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.